# US 2024/0201186 A1 · Triage biomarkers and use therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201186 A1
- Document ID: US20240201186A1
- Status: Published application
- Kind: A1
- Application number: 18/596,338
- Filed: 2024-03-05
- Published: 2024-06-20
- Earliest claimed: 2015-12-24
- Assignees: Immunexpress Pty Ltd
- Applicants: ImmuneXpress Pty Ltd
- Inventors: Richard Bruce Brandon; Brian Andrew Fox; Leo Charles McHugh; Dayle Lorand Sampson
- Web page: https://patentgrep.com/patent/US20240201186A1

## CPC

- G01N 33/56911: {Bacteria}
- A61B 5/412: {Detecting or monitoring sepsis}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/158: Expression markers
- G01N 2469/00: Immunoassays for the detection of microorganisms
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed are methods, apparatus, kits and compositions for determining the absence of a systemic bacterial infection (sepsis) in patients, particularly ones presenting to hospital emergency departments (ED) as outpatients, by measurement of the host immune response using peripheral blood. The are methods, apparatus, kits and compositions can be used in mammals for diagnosing, making treatment decisions, determining the next procedure or diagnostic test, or management of patients suspected of having an infection, including those presenting with fever or other signs of systemic inflammation. More particularly, peripheral blood RNA and protein biomarkers are disclosed that are useful for distinguishing between the host immune response to bacteria compared to the host immune response to other causes of systemic inflammation including trauma, burns, autoimmune disease, asthma, anaphylaxis, arthritis, obesity and viral infections. As such, the biomarkers are useful for distinguishing bacterial-associated systemic inflammatory response syndrome from non-bacterial systemic inflammation to provide clinicians with strong negative predictive value (>95%) so that sepsis can be excluded as a diagnosis in patients presenting to ED with clinical signs of systemic inflammation.

## Claims

### Claim at position 1

-55. (canceled)

### Claim 56

A composition comprising a DNA polymerase, whole peripheral blood leukocyte cDNA from a subject with a clinical sign of systemic inflammatory response syndrome (SIRS), wherein the whole peripheral blood leukocyte cDNA comprises a guanylate binding protein 2 (GBP2) cDNA and one or both of a GTPase IMAP family member 4 (GIMAP4) cDNA and a Toll-like receptor 5 (TLR5) cDNA, wherein the composition further comprises for each cDNA two oligonucleotide primers that hybridize to opposite complementary strands of the cDNA.

### Claim 57 (depends on 56)

The composition of claim 56, further comprising for each cDNA an oligonucleotide probe that hybridizes to the cDNA and that comprises a reporter molecule.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the oligonucleotide probe comprises a fluorescent label.

### Claim 59 (depends on 57)

The composition of claim 57, wherein the oligonucleotide probe comprises a fluorescent label and a quencher molecule.

### Claim 60 (depends on 57)

The composition of claim 57, wherein the oligonucleotide probe is a real-time polymerase chain reaction probe.

### Claim 61 (depends on 57)

The composition of claim 57, wherein the oligonucleotide probe is a TaqMan® probe.

### Claim 62 (depends on 57)

The composition of claim 57, wherein the oligonucleotide probe that hybridizes to one of the cDNAs comprises a detectably different reporter molecule than the reporter molecule of the oligonucleotide probe that hybridizes to another of the cDNAs.

### Claim 63 (depends on 56)

The composition of claim 56, wherein the DNA polymerase is a thermostable DNA polymerase.

### Claim 64 (depends on 63)

The composition of claim 63, wherein the DNA polymerase is a Taq polymerase.

### Claim 65 (depends on 56)

The composition of claim 56, wherein the composition comprises two oligonucleotide primers that hybridize to opposite complementary strands of the GBP2 cDNA and two oligonucleotide primers that hybridize to opposite complementary strands of the GIMAP4 cDNA.

### Claim 66 (depends on 65)

The composition of claim 65, further comprising a first oligonucleotide probe that hybridizes to the GBP2 cDNA and that comprises a first reporter molecule and a second oligonucleotide probe that hybridizes to the GIMAP4 cDNA and that comprises a second reporter molecule.

### Claim 67 (depends on 56)

The composition of claim 56, wherein the composition comprises two oligonucleotide primers that hybridize to opposite complementary strands of the GBP2 cDNA and two oligonucleotide primers that hybridize to opposite complementary strands of the TLR5 cDNA.

### Claim 68 (depends on 67)

The composition of claim 67, further comprising a first oligonucleotide probe that hybridizes to the GBP2 cDNA and that comprises a first reporter molecule and a second oligonucleotide probe that hybridizes to the TLR5 cDNA and that comprises a second reporter molecule.

### Claim 69 (depends on 56)

The composition of claim 56, wherein the composition comprises two oligonucleotide primers that hybridize to opposite complementary strands of the GBP2 cDNA, two oligonucleotide primers that hybridize to opposite complementary strands of the GIMAP4 cDNA, and two oligonucleotide primers that hybridize to opposite complementary strands of the TLR5 cDNA.

### Claim 70 (depends on 69)

The composition of claim 69, further comprising a first oligonucleotide probe that hybridizes to the GBP2 cDNA and that comprises a first reporter molecule, a second oligonucleotide probe that hybridizes to the GIMAP4 cDNA and that comprises a second reporter molecule, and a third oligonucleotide probe that hybridizes to the TLR5 cDNA and that comprises a third reporter molecule.
